What is your preferred third line approach for a patient with refractory small cell lung cancer who has failed second line therapy with nivolumab after recieving first line platinum based therapy ?
Would you offer immunotherapy combination (nivo/ipi) in patients who have failed nivolumab mono-therapy?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Minnesota
Answered on
I would prefer a clinical trial or perhaps a taxane, but I have added ipilimumab to nivolumab in this situation, despite the lack of data. The results remain to be seen!
Join for free or sign in to see the full answer